New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 10, 2012
04:20 EDTLULU, ROST, AAPL, WWE, NILE, EOG, CELG, CMG, APU, ATML, SMG, AGN, SBUX, ZNGA, INTCJim Cramer's "Mad Money"
Jim Cramer said that if investors really want to sell, they should take a deep breath and wait, but even more prudent would be to do a little buying.He explained that selling into a panic is often the worst time to sell. Cramer recalled the seven great American growth stocks he featured in April, stocks that included Apple (AAPL), Starbucks (SBUX), Chipotle Mexican Grill (CMG), Ross Stores (ROST), Allergan (AGN), Celgene (CELG) and Lululemon Athletica (LULU). All of these names, he said, are the perfect stocks to revisit after this week's market pullback. In all seven cases, Cramer said that these companies have superior growth, excellent management and long-term trends that transcend the market's short-term volatility. He said, the smart move would be to wait for the markets to take these great names lower and scoop them up while they're on sale. EXECUTIVE DECISION: Cramer sat down with Jim Hagedorn, chairman and CEO of Scotts Miracle-Gro (SMG), a stock that was hammered down 16% in Tuesday's trading after the company delivered a mixed quarter with a 9c earnings beat on lighter-than-expected revenue. Scotts currently yields 2.55%. Hagedorn said the company is meeting all of its internal expectations and is growing sales and taking share, but it simply couldn't meet the inflated expectations that the analysts had cooked up. Cramer remained bullish on Scotts after what was undoubtedly a strong quarter that was totally misunderstood by Wall Street. Then, Cramer once again spoke with Mark Papa, chairman and CEO of EOG Resources (EOG), an oil shale driller that posted a 3c earnings beat on a 47% yoy rise in revenue and a 49% increase in oil production. Papa explained that unlike other oil drillers, EOG is growing organically "through the drill bit" and is offering investors a higher rate of return by doing so. Cramer continued his support of EOG Resources. NO HUDDLE OFFENSE: Cramer said when it comes to secure stocks to own in 2012, both AT&T and Verizon offer growth, expanding gross margins and most importantly, no exposure to the chaos in Europe. LIGHTNING ROUND: (Bullish) INTC. (Bearish) ATML; NILE; ZNGA; APU; WWE. Reference Link
News For AAPL;SBUX;CMG;ROST;AGN;CELG;LULU;SMG;EOG;INTC;ATML;NILE;ZNGA;APU;WWE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
February 18, 2015
17:15 EDTEOGEOG Resources expects to complete about 45% fewer wells in FY15
EOG's primary goal for 2015 is to position the company to resume long-term growth once crude oil prices recover. The company is not interested in accelerating crude oil production in a low-price environment. Capital expenditures for 2015 are expected to range from $4.9B-$5.1B, including production facilities and midstream expenditures, and excluding acquisitions. This 40 percent reduction compared to 2014 reflects EOG's commitment to capital discipline in a low crude oil price environment. Capital will be allocated primarily to EOG's highest rate-of-return oil assets, the Eagle Ford, Delaware Basin and Bakken plays. To further enhance capital efficiency, EOG plans to utilize rigs under existing commitments and delay a significant number of completions. Delaying completions increases returns, adds substantial net present value and prepares the company to resume strong oil growth when commodity prices recover. Due to reduced capital spending and delayed completions, EOG expects to complete approximately 45% fewer wells in 2015 versus 2014. Therefore, the midpoint for 2015 total company crude oil production guidance is essentially flat year over year. Once again, EOG plans to minimize investment in domestic dry natural gas drilling. As a result, its U.S. natural gas production and total company production are expected to decline modestly. Year after year, EOG has relentlessly focused on advancing its industry-leading completion technology and driving down unit costs through efficiency gains. That will not change in 2015. Finally, the company expects to use its strong balance sheet to capitalize on unique opportunities created by this low-price environment to add high-quality acreage.
17:14 EDTEOGEOG Resources reports Q4 EPS 79c, consensus $1.02
Reports Q4 revenue $4.65B, consensus $4.14B.
16:46 EDTAGNOn The Fly: Closing Wrap
Subscribe for More Information
16:00 EDTAAPL, CELGOptions Update; February 18, 2015
Subscribe for More Information
15:35 EDTEOGNotable companies reporting after market close
Subscribe for More Information
12:31 EDTAGNOn The Fly: Midday Wrap
Subscribe for More Information
12:17 EDTSBUXStarbucks management to meet with Piper Jaffray
Subscribe for More Information
10:05 EDTCELGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:48 EDTAGNActavis Q4 'exceptional,' taking Allergan name 'wise,' says BMO Capital
BMO Capital says Actavis (ACT) is "firing on all cylinders" after reporting "exceptional" Q4 earnings on the strength of the company's North American Generics and International segment. BMO views the decision to adopt the Allergan (AGN) name as "wise" given the Botox maker's strong reputation. The firm keeps an Outperform rating on Actavis.
09:38 EDTCELGCelgene reports FDA expands indication for Revlimid combo
Subscribe for More Information
09:37 EDTAAPL, CELGOption volume leaders on open
Option volume leaders: AAPL TSLA TWTR CELG APO NFLX AXP APA LNKD C GILD according to Track Data.
09:28 EDTEOGEOG Resources volatility increases into Q4 results and outlook
Subscribe for More Information
07:59 EDTAAPLBlackBerry files copyright lawsuit against Typo Products, AP says
Subscribe for More Information
07:50 EDTAGNActavis CEO says company gave appropriate guidance to analysts
Actavis (ACT) CEO Saunders said he believes that the company did provide appropriate guidance to analysts ahead of its earnings beat. Saunders sees the Allergan (AGN) deal closing by the end of this quarter or early next quarter. Saunders says tying R&D to a percentage of revenue "makes no sense to me," noting that Actavis will spend about $1.7B on R&D next year. Saunders says will do acquisition if opportunity arises, but not planning for M&A right now. Actavis CEO Brent Saunders is speaking on CNBC.
07:01 EDTAGNActavis announces intention to adopt 'Allergan' corporate name
Subscribe for More Information
06:52 EDTAAPLApple could bringing Touch ID to Mac, 9to5Mac says
Subscribe for More Information
06:47 EDTCELGCelgene initiated with a Buy at Canaccord
Target $156.
06:45 EDTAAPLApple Watch launching without health monitoring functions, WSJ says
Subscribe for More Information
06:34 EDTAGNActavis sees Allergan transaction completed in late Q1 or early Q2
06:20 EDTAAPLApple awarded patent for wireless head-mounted display, Financial Times reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use